PARK19 (DNAJC6-Related Parkinson's Disease)

PARK19 (DNAJC6-Related Parkinson's Disease)

Overview

PARK19 is an autosomal recessive form of early-onset [Parkinson's disease](/diseases/parkinsons-disease-disease) caused by biallelic loss-of-function mutations in the DNAJC6 gene (also known as auxilin-2). This form of PD is characterized by onset typically before age 30, rapid progression, and generally good response to levodopa therapy [1](https://pubmed.ncbi.nlm.nih.gov/33983693/) [2](https://pubmed.ncbi.nlm.nih.gov/26528954/). DNAJC6-related PD represents one of the rarer monogenic forms of parkinsonism, accounting for a small percentage of early-onset cases. [@lrrk2018]

The identification of DNAJC6 as a PD-causing gene highlights the importance of synaptic vesicle cycling in dopaminergic neuron survival. Unlike other PARK genes involved in mitochondrial quality control (PARK2/Parkin, PINK1) or protein aggregation (SNCA, GBA), DNAJC6 mutations disrupt the fundamental process of synaptic vesicle endocytosis [3](https://pubmed.ncbi.nlm.nih.gov/36920906/) [4](https://pubmed.ncbi.nlm.nih.gov/38595283/). [@synaptic2024]

Historical Background

Discovery

The link between DNAJC6 and Parkinson's disease was first established through genetic studies of consanguineous families with early-onset parkinsonism. Initial reports in 2012 by Edvardson et al. described homozygous mutations in DNAJC6 in patients with juvenile-onset PD [5](https://pubmed.ncbi.nlm.nih.gov/22294215/). Subsequent studies have identified additional pathogenic variants and refined our understanding of the phenotype. [@monogenic2010]

PARK19 (DNAJC6-Related Parkinson's Disease)

Overview

PARK19 is an autosomal recessive form of early-onset [Parkinson's disease](/diseases/parkinsons-disease-disease) caused by biallelic loss-of-function mutations in the DNAJC6 gene (also known as auxilin-2). This form of PD is characterized by onset typically before age 30, rapid progression, and generally good response to levodopa therapy [1](https://pubmed.ncbi.nlm.nih.gov/33983693/) [2](https://pubmed.ncbi.nlm.nih.gov/26528954/). DNAJC6-related PD represents one of the rarer monogenic forms of parkinsonism, accounting for a small percentage of early-onset cases. [@lrrk2018]

The identification of DNAJC6 as a PD-causing gene highlights the importance of synaptic vesicle cycling in dopaminergic neuron survival. Unlike other PARK genes involved in mitochondrial quality control (PARK2/Parkin, PINK1) or protein aggregation (SNCA, GBA), DNAJC6 mutations disrupt the fundamental process of synaptic vesicle endocytosis [3](https://pubmed.ncbi.nlm.nih.gov/36920906/) [4](https://pubmed.ncbi.nlm.nih.gov/38595283/). [@synaptic2024]

Historical Background

Discovery

The link between DNAJC6 and Parkinson's disease was first established through genetic studies of consanguineous families with early-onset parkinsonism. Initial reports in 2012 by Edvardson et al. described homozygous mutations in DNAJC6 in patients with juvenile-onset PD [5](https://pubmed.ncbi.nlm.nih.gov/22294215/). Subsequent studies have identified additional pathogenic variants and refined our understanding of the phenotype. [@monogenic2010]

Nomenclature

• PARK19: Numerical designation in the PARK gene nomenclature system
• DNAJC6: DnaJ heat shock protein family (Hsp40) member C6
• Auxilin-2: Originally named for its similarity to auxilin-1 (DNAJC5), involved in synaptic vesicle recycling

Genetics

| Attribute | Value | [@monogenic2022]
|-----------|-------| [@genetics2020]
| Gene | [DNAJC6](/genes/dnajc6) | [@auxilin]
| Previous Symbol | Auxilin-2 | [@clathrinmediated]
| Inheritance | Autosomal recessive | [@hsp]
| Chromosome | 19q13.43 | [@genetic]
| OMIM | [OMIM: 613335](https://www.omim.org/entry/613335) | [@therapeutic]
| Protein | Auxilin-2 (Hsp40 co-chaperone) |
| Protein Family | DnaJ/Hsp40 chaperone family |
| Exon Count | 20 exons |
| Transcript Length | 3.8 kb coding sequence |

Gene Structure and Function

The DNAJC6 gene encodes a protein of 1,128 amino acids with several functional domains:

The J domain is essential for the co-chaperone function, while the clathrin-binding regions direct the protein to sites of synaptic vesicle endocytosis [6](https://pubmed.ncbi.nlm.nih.gov/24731329/).

Known Pathogenic Variants

| Variant | Type | Effect | First Identified | Population |
|---------|------|--------|-----------------|------------|
| p.Leu275Pro | Missense | Loss of function | Koh et al., 2014 | Korean |
| p.Gly849Arg | Missense | Loss of function | Edvardson et al., 2012 | Palestinian |
| c.801-1G>A | Splicing | Loss of function | Elsayed et al., 2016 | Egyptian |
| p.Arg363* | Nonsense | Truncated protein | Zhang et al., 2021 | Chinese |
| p.Arg519His | Missense | Loss of function | Olavarría et al., 2019 | Chilean |
| Exon deletions | Large deletion | Loss of function | Multiple families | Various |
| c.2389+1G>A | Splicing | Loss of function | Local et al., 2018 | Turkish |

Variant Classification

Pathogenic variants in DNAJC6 are predominantly loss-of-function mutations:

• Nonsense mutations create premature termination codons
• Splicing mutations disrupt mRNA processing
• Missense mutations impair protein function
• Large deletions remove critical protein domains

Population Frequency

DNAJC6 pathogenic variants are rare in the general population. Carrier frequency estimates suggest:

• European descent: ~1 in 500-1,000
• East Asian: ~1 in 1,000-2,000
• Middle Eastern: Higher due to consanguinity [7](https://pubmed.ncbi.nlm.nih.gov/27687717/) [8](https://pubmed.ncbi.nlm.nih.gov/30373961/)

Clinical Features

Core Motor Symptoms

• Early onset: Typically before age 30, often in adolescence or early adulthood
• Rapid progression: Early development of motor complications compared to idiopathic PD
• Good levodopa response: Patients respond well to dopaminergic therapy
• Typical PD signs: Resting tremor, bradykinesia, rigidity, postural instability
• Parkinsonism asymmetry: Often begins asymmetrically [9](https://pubmed.ncbi.nlm.nih.gov/33181391/)

Non-Motor Symptoms

• Cognitive impairment: Variable; some patients develop dementia
• Psychiatric symptoms: Depression, anxiety, and behavioral changes
• Sleep disorders: REM sleep behavior disorder (RBD) in some cases
• Autonomic dysfunction: Constipation, orthostatic hypotension
• Olfactory dysfunction: Variable; not universal

Phenotypic Spectrum

| Phenotype | Features | Frequency |
|-----------|----------|----------|
| Juvenile PD | Onset <20 years | ~40% |
| Early-onset PD | Onset 20-40 years | ~60% |
| Atypical features | Dystonia, myoclonus | ~25% |

Clinical Presentation Variability

While the core phenotype is consistent, significant variability exists:

• Age of onset can range from 12 to 45 years
• Some patients present with dystonia as the initial symptom
• Tremor-dominant and postural instability/gait difficulty subtypes both occur
• Cognitive decline may or may not develop

Pathophysiology

DNAJC6/Auxilin-2 has two key functions that, when disrupted, lead to neurodegeneration [10](https://pubmed.ncbi.nlm.nih.gov/33597231/) [11](https://pubmed.ncbi.nlm.nih.gov/29735704/):

1. Synaptic Vesicle Recycling Defect

DNAJC6 is a neuronal co-chaperone that assists Hsc70 (heat shock cognate 70) in clathrin-mediated endocytosis. Loss of function impairs synaptic vesicle recycling, leading to:

• Depletion of synaptic vesicle pools
• Impaired dopamine release
• Accumulation of clathrin-coated intermediates
• Secondary mitochondrial dysfunction

The synaptic vesicle cycle involves several critical steps:

DNAJC6 acts specifically at the uncoating step, making it essential for rapid vesicle recycling [12](https://pubmed.ncbi.nlm.nih.gov/38595283/).

2. Mitochondrial Dysfunction

The synaptic vesicle recycling defect leads to secondary mitochondrial impairment:

• Increased energy demands from failed vesicle recycling
• Calcium dysregulation at synapses
• Enhanced vulnerability to oxidative stress
• Impaired mitophagy due to energy depletion

3. Protein Homeostasis Disruption

Beyond synaptic vesicle cycling, DNAJC6 loss affects cellular protein quality control:

• Impaired chaperone function affects misfolded protein clearance
• Synaptic proteins may aggregate due to improper processing
• Endoplasmic reticulum stress response activation

LRRK2 Interaction

Recent research has revealed an important interaction between DNAJC6 and [LRRK2](/entities/lrrk2) (leucine-rich repeat kinase 2), another major PD-causing gene [13](https://pubmed.ncbi.nlm.nih.gov/20301402/):

• LRRK2 phosphorylates auxilin at specific serine residues
• This phosphorylation regulates auxilin's interaction with clathrin
• LRRK2 mutations associated with PD may impair this regulation
• Suggests common pathway convergence

Comparison with Other PARK Genes

| Gene | Primary Function | Pathway | Typical Pathology |
|------|-----------------|---------|-----------------|
| DNAJC6 | Synaptic vesicle recycling | Endocytosis | Lewy bodies |
| PRKN (Parkin) | Mitochondrial quality control | Mitophagy | Variable Lewy bodies |
| PINK1 | Mitochondrial surveillance | Mitophagy | Lewy bodies |
| SNCA | Synaptic function | Protein aggregation | Lewy bodies |
| LRRK2 | Membrane trafficking | Kinase signaling | Lewy bodies |

Diagnosis

Clinical Criteria

Diagnostic Workup

| Step | Test | Purpose |
|------|------|---------|
| 1 | Neurological examination | Document parkinsonism |
| 2 | DaTscan | Confirm dopaminergic deficit |
| 3 | MRI brain | Rule out structural causes |
| 4 | Genetic testing | Confirm DNAJC6 mutation |

Genetic Testing

| Method | Detection Rate | Comments |
|--------|---------------|----------|
| Panel sequencing | 60-70% | Most common first test |
| Whole exome sequencing | 70-80% | Broader detection |
| Whole genome sequencing | ~80% | Detects intronic variants |
| Deletion/duplication analysis | 10-15% | Important for exon deletions |

Differential Diagnosis

• PARK2 (Parkin): Similar early onset, but typically lacks Lewy bodies
• PINK1: Often has earlier onset, sleep benefit
• ATP13A2 (PARK9): More severe, includes dementia
• FBXO7: Often has pyramidal signs
• Idiopathic PD: Later onset, different progression

Treatment

Pharmacological Management

| Treatment | Efficacy | Notes |
|-----------|----------|-------|
| Levodopa/Carbidopa | Excellent | First-line; early benefit |
| Dopamine agonists | Good | Pramipexole, ropinirole |
| MAO-B inhibitors | Moderate | Selegiline, rasagiline |
| COMT inhibitors | Adjunct | Entacapone for wearing-off |

Treatment of DNAJC6-related PD follows standard PD protocols but with some specific considerations [14](https://pubmed.ncbi.nlm.nih.gov/35248242/) [15](https://pubmed.ncbi.nlm.nih.gov/32861274/):

Special Considerations

Motor Complications:

• Earlier development of dyskinesias compared to idiopathic PD
• Lower threshold for dyskinesia management
• May require fractionated dosing

• Psychiatric symptoms: SSRIs, careful antipsychotic selection
• Sleep disorders: Melatonin, clonazepam for RBD
• Constipation: Fiber, laxatives, hydration

Disease-Modifying Approaches

No disease-modifying therapies are specifically approved for PARK19, but several strategies are under investigation:

• AAV-mediated gene therapy: Deliver functional DNAJC6
• Small molecule co-chaperone activators: Enhance residual function
• Antioxidants: Combat secondary mitochondrial dysfunction
• Synaptic vesicle modulators: Improve vesicle cycling
• LRRK2 inhibitors: If LRRK2 interaction is relevant

Research Models

Cellular Models

• Patient-derived iPSCs: Dopaminergic [neurons](/entities/neurons) with DNAJC6 mutations show impaired synaptic vesicle trafficking and increased sensitivity to oxidative stress
• Knockdown systems: siRNA-mediated DNAJC6 depletion reproduces key phenotypes
• CRISPR models: Gene editing to introduce known pathogenic variants

Animal Models

• C. elegans: Knockout shows dopamine neuron degeneration
• Drosophila: Models recapitulate motor deficits
• Mouse: Conditional knockout under development

Prevalence

PARK19 is one of the rarer monogenic forms of PD:

| Population | Estimated % of EOPD |
|------------|-------------------|
| Worldwide | 0.5-1.0% |
| Middle East | 2-3% (consanguinity) |
| Specific cohorts | Up to 4% in juvenile PD |

Family Counseling

Inheritance Pattern

• Autosomal recessive: both copies must be mutated
• Each parent is typically a heterozygous carrier
• 25% risk for each pregnancy
• Siblings of affected individuals: 25% affected, 50% carriers

Genetic Counseling Points

Future Directions

Unanswered Questions

Emerging Therapies

• Gene replacement: AAV vectors carrying functional DNAJC6
• Protein aggregation inhibitors: Targeting secondary protein aggregation
• Synaptic function enhancers: Improving vesicle cycling
• Combination approaches: Multiple targets for synergistic effects

Cross-Links

Related Genes

• [DNAJC6](/genes/dnajc6) - The causative gene
• [LRRK2](/genes/lrrk2) - Interacting protein
• [DNAJC5](/genes/dnajc5) - Auxilin-1, related protein
• [PARK2](/genes/parkin) - Other early-onset PD gene
• [PINK1](/genes/pink1) - Mitochondrial PD gene

Related Mechanisms

• [Synaptic vesicle cycling](/mechanisms/synaptic-vesicle-cycling) - Affected pathway
• [Clathrin-mediated endocytosis](/mechanisms/clathrin-endocytosis) - Primary defect
• [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration) - Secondary effect

Related Diseases

• [Parkinson's disease](/diseases/parkinsons-disease) - Core disease
• [Early-onset Parkinson's disease](/diseases/early-onset-parkinsons) - Disease category
• [Juvenile Parkinson's disease](/diseases/juvenile-parkinsons) - Phenotype

See Also

• [DNAJC6](/genes/dnajc6)
• [Parkinson's disease](/diseases/parkinsons-disease)
• [Early-onset Parkinson's disease](/diseases/early-onset-parkinsons)
• [Synaptic vesicle cycling](/mechanisms/synaptic-vesicle-cycling)
• [LRRK2](/genes/lrrk2)

References